%0 Journal Article
%T Ibrutinib-induced cardiomyopathy
%A Htay Htay Kyi
%A Samer Al Hadidi
%A Yazan Zayed
%J Journal of Community Hospital Internal Medicine Perspectives
%D 2019
%R https://doi.org/10.1080/20009666.2018.1555432
%X ABSTRACT The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital with new-onset atrial fibrillation and symptomatic systolic congestive heart failure one month after ibrutinib initiation. Although ibrutinib was discontinued, the patient continues to have a low ejection fraction four months after discontinuation. Ischemic heart disease was ruled out with normal cardiac catheterization. This case highlights a possible new side effect of ibrutinib that needs to be monitored while patients receive this medication
%U https://www.tandfonline.com/doi/full/10.1080/20009666.2018.1555432